RALEIGH, North Carolina: PRA International, a leading Clinical Research Organization, announces
our recent acquisition of Kinship Technologies, a Chennai, India-based
software developer and services company. PRA will obtain Kinship's industry
changing system, EXACT, and is integrating the Kinship team to accelerate the
development of technology solutions that will enhance PRA's service delivery
and reshape how the industry manages trials and delivers trial data.
"The process of how data is converted and analyzed in our industry has
remained unchanged for over 20 years; with the increasing prevalence of CDISC
standards, we felt the need to significantly change the process to create a
more efficient delivery model and provide our customers more validation and
visibility into our work," said Steve Powell, PRA's Senior VP of Clinical
Informatics & Late Phase Services. "When we found Kinship Technologies and
implemented the EXACT system, we knew we had discovered a game changer."
Kinship's flagship product, EXACT, is a revolutionary system that allows
users to quickly construct reusable programs for data extraction, data
transformation, statistical reporting and electronic publishing in a visual
environment with limited code writing. PRA will use the EXACT system to
simplify and automate the production of multiple CDISC standards as well as
tables, figures, and listings (TFLs) in reports.
"The EXACT system allows programmers and biostatisticians to spend more
time delivering higher value services to our clients instead of spending time
writing and validating programs that only extract, transform, or layout
clinical data," said Jason Packwood, Vice President of PRA's Business
Solutions group, which directs our systems management and process improvement
projects. "Through its powerful global metadata repository, the Kinship
product allows users to quickly produce SDTM and ADaM datasets, DEFINE.XML
documents, and TFLs."
The Kinship EXACT product offers numerous benefits and features to PRA
and our clients, including significant efficiencies, new library management
capabilities, streamlined processes for documentation, and improved quality
and reliability. By acquiring Kinship, which has been serving pharmaceutical
and biotech companies since 1996, PRA also furthers a strategic initiative to
establish a "center of excellence" for software product development, enabling
PRA's commitment to leverage technology to improve clinical trials.
"Kinship is proud and excited to have merged with PRA," said Giri
Balasubramanian, Director of Kinship Technologies. "PRA and Kinship share the
same goals of transforming clinical trial processes by enhancing both the
value and global presence of EXACT. We are committed to taking EXACT to the
world's leading pharmaceutical organizations using our companies' expertise
in product development."
PRA's goal is to create a high-quality, efficient, paperless,
data-driven, end-to-end clinical management delivery process. In addition to
the EXACT software, we have begun integrating other state-of-the-art
eClinical solutions company-wide, to enhance client service and to position
ourselves for future trends in trial delivery.
For more information about Kinship EXACT, please visit
http://www.kinshiptech.com.
About PRA
PRA conducts clinical trials across all therapeutic areas in more than 80
countries and provides services in all phases of clinical development through
its 40 global offices.
PRA's therapeutic expertise, global reach and project experience combined
with its extensive local knowledge and differentiating philosophy-THE
PERSONAL ELEMENT- enable its project teams to deliver consistent and on-time
performance. This unique PRA philosophy recognizes that true client service
comes only from trained, empowered and dedicated employees who are encouraged
to be innovative and to use their personal commitment to accelerate the
development life cycle.
To learn more about PRA International, please visit
http://www.PRAinternational.com, email Endpoints@PRAintl.com or call our
Global Headquarters at +1-919-786-8200.